Report
Pierre-Antoine Bourgoin
EUR 1000.00 For Business Accounts Only

Nanobiotix - Assemblée Générale des actionnaires du 28 avril 2020

La rémunération totale attribuée au titre de l’exercice 2019 à Laurent Levy s’élève à 2 502 957 €, soit 407% de la médiane des rémunérations totales des dirigeants du Top 250. En raison du montant excessif, nous recommandons l'opposition (résolution 8).
Concernant sa politique de rémunération, nous ne soutenons pas la résolution eu égard au manque de transparence de la société, notamment sur la rémunération variable annuelle et de long terme pouvant amener à une rémunération également excessive (résolution 16).

Enfin, au regard des dernières informations disponibles (notamment le nombre d’options et d’actions en circulation au 31/12/2019 pouvant donner accès à un total de 2 481 739 actions (soit 11,07 % du capital), tel qu’indiqué dans le rapport de gestion de la société (p.62)), la dilution potentielle liée aux autorisations d'émissions d'instruments financiers consentis aux salariés et mandataires sociaux (le nombre total d'options et actions de performance ou gratuits en circulation plus les nouvelles autorisations) est estimée à 13,75% du capital.

Underlying
Nanobiotix SA

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. Specifically, NanoXray products may overcome the current limitations of standard of care in local therapy. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Provider
Proxinvest
Proxinvest

Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.

Proxinvest main services are :

  • ​Proxy reports
  • Definition and monitoring of client customized voting guidelines
  • Corporate Governance Data and Rating
  • Thematic research
  • Engagement support

Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.

Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.

As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide. 

Analysts
Pierre-Antoine Bourgoin

Other Reports on these Companies
Other Reports from Proxinvest

ResearchPool Subscriptions

Get the most out of your insights

Get in touch